Tìm theo
Rituximab
Các tên gọi khác (2) :
  • AntiCD20
  • Ig gamma-1 chain C region
Thuốc điều trị ung thư
Thuốc Gốc
Biotech
CAS: 174722-31-7
ATC: L01XC02
ĐG : Biogen Idec Inc. , http://www.biogenidec.com
CTHH: C6416H9874N1688O1987S44
PTK: 143859.7000
Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C6416H9874N1688O1987S44
Phân tử khối
143859.7000
Độ tan chảy
61 °C (FAB fragment), 71 °C (whole mAb)
Độ kỵ nước
-0.414
Điểm đẳng điện tích
8.68
Dược Lực Học : Rituximab binds to the CD20 antigen, which is predominantly expressed on mature B cells and on >90% of B-cell non-Hodgkin's lympohomas. The antibody leads to selective killing of B-cells.
Cơ Chế Tác Dụng : Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids The Fab regions of rituximab binds to the CD20 antigen on B lymphocytes, while the Fc domain recruits antibodies and complements to mediate cell lysis.
Dược Động Học :

▧ Volume of Distribution :
* 3.1 L
▧ Metabolism :
Most likely removed by opsonization via the reticuloendothelial system when bound to B lymphocytes, or by human antimurine antibody production
▧ Half Life :
0.8 hours (mammalian reticulocytes, in vitro)
▧ Clearance :
* 0.34 L/day [RA patients]
Chỉ Định : For treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
Tương Tác Thuốc :
  • Abatacept Avoid combination due to enhanced adverse effects of abatacept.
  • Aliskiren Consider therapy modification due to enhanced hypotensive effect of rituximab.
  • Azilsartan medoxomil Azilsartan medoxomil used in combination with rituximab may lead to hypotension.
  • Betaxolol Antihypertensives like betaxolol may enhance the hypotensive effect of rituximab. Consider temporarily withholding antihypertensive medications for 12 hours prior to rituximab infusion to avoid excessive hypotension during or immediately after infusion.
  • Certolizumab pegol Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended.
  • Chlorothiazide Antihypertensives such as chlorothiazide may enhance the hypotensive effect of Rituximab. Consider temporarily withholding antihypertensive medications for 12 hours prior to rituximab infusion to avoid excessive hypotension during or immediately after infusion.
  • Telmisartan Telmisartan may increase the hypotensive effect of Rituximab. Telmisartan should be withheld prior to and throughout Rituximab administration.
  • Terazosin Additive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Terazosin for 12 hours prior to administration of Rituximab.
  • Tofacitinib Avoid combination due to the potential increase in tofacitinib related adverse effects.
  • Tolazamide Additive hypotensive effects may occur. Consider withholding Tolazamide for 12 hours prior to administration of Rituximab.
  • Torasemide Additive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Torasemide for 12 hours prior to administration of Rituximab.
  • Trandolapril Trandolapril may incresae the hypotensive effect of Rituximab.
  • Trastuzumab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
  • Trichlormethiazide Additive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Trichlormethiazide for 12 hours prior to administration of Rituximab.
  • Valsartan Additive hypotensive effects may occur. Increased risk of hypotension. Consider withholding Valsartan for 12 hours prior to administration of Rituximab.
  • Verapamil Verapamil may increase the hypotensive effects of Rituximab. Consider withholding Verapamil therapy for 12 hours prior to Rituximab infusion.
Liều Lượng & Cách Dùng : Solution - Intravenous
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty : Roche
    Sản phẩm biệt dược : MabThera
  • Công ty : Genentech Inc
    Sản phẩm biệt dược : Rituxan
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00073
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/50242-053-06
GenBank
http://www.ncbi.nlm.nih.gov/nuccore/J00228
PharmGKB
http://www.pharmgkb.org/drug/PA451261
Wikipedia
http://en.wikipedia.org/wiki/Rituximab
RxList
http://www.rxlist.com/cgi/generic/ritux.htm
Drugs.com
http://www.drugs.com/cdi/rituximab.html
... loading
... loading